Suppression of cytotoxic effect of mitomycin-C by superoxide dismutase in Fanconi's anemia and dyskeratosis congenita fibroblasts

Carcinogenesis
H Nagasawa, J B Little

Abstract

Survival curves were determined for several human diploid fibroblast strains treated with mitomycin-C (MMC) with or without concomitant incubation with superoxide dismutase (SOD). These included cells from patients with Fanconi's anemia (FA), dyskeratosis congenita (DC) a disorder related to FA, Gardner's syndrome (GS) and xeroderma pigmentosum grop C (XPC). Incubation with SOD had no effect on MMC-induced cytotoxicity in the two normal cell strains, XPC or GS. Although GM2053 (FA) and two DC strains showed intermediate sensitivity to killing by MMC similar to XPC and GS, the survival of these cell strains was increased approximately 2-4 times after 0.5 microgram/ml of MMC by concomitant treatment with SOD. Survival of the most MMC sensitive cell strain GM1309 (FA) was sharply increased by adding SOD; survival was enhanced about 15-fold after treatment with 0.1 microgram/ml of MMC. SOD induced no enhancement of survival in MMC treated normal cells at survival levels down to nearly 10(-3). We propose that the hypersensitivity to MMC cytoxicity in FA and DC cells may involve among other factors a deficiency in the inactivation of certain free radical intermediates.

Citations

May 10, 2002·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Shamim I AhmadSandra H Kirk
Mar 1, 1994·Stem Cells·C C dos SantosM Buchwald
Jan 1, 1986·Journal of Inherited Metabolic Disease·C F Arlett
Mar 1, 1988·Mutation Research·H NagasawaJ B Little
Sep 1, 1986·Mutation Research·G Duckworth-RysieckiM Buchwald
Nov 25, 1998·British Journal of Haematology·A A ClarkeT R Rutherford
Oct 1, 1993·British Journal of Haematology·J M LiuN S Young
Dec 1, 1988·Journal of Medical Genetics·H R Davidson, J M Connor
Sep 27, 2008·Journal of Clinical Biochemistry and Nutrition·Mi Ra YoonMi Young Kang
Sep 26, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J CarrilloR Perona
Jun 28, 2012·Anemia·Tagrid Kaddar, Madeleine Carreau
Feb 1, 1993·American Journal of Hematology·J C Schultz, N T Shahidi
Jan 1, 1989·Baillière's Clinical Haematology·E C Gordon-Smith, T R Rutherford
Mar 4, 2015·Pediatric Blood & Cancer·Giovanni PaganoFederico V Pallardó
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Frank A. E. Kruyt, Hagop Youssoufian
Jan 1, 1987·CRC Critical Reviews in Biochemistry·J V BannisterG Rotilio
Apr 2, 2016·Nature Communications·Sara JaberFranck Toledo
Jul 8, 2005·European Journal of Haematology·Giovanni PaganoAdriana Zatterale
Mar 1, 1997·Seminars in Cutaneous Medicine and Surgery·R E Schnur, W R Heymann
Mar 1, 1986·Cancer Treatment Reviews·A Petkau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.